In a regulatory filing, CalciMedica said it had raised $9.2m. Two-thirds of this money is released following a clinical milestone for its CM2489 once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.
CalciMedica, a US-based healthcare company backed by listed drugs companies Biogen Idec and GlaxoSmithKline’s corporate venturing units, has raised $9m from six investors.
In a regulatory filing, CalciMedica said it had raised $9.2m but two-thirds of this money is released following a clinical milestone for its CM2489 once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.
CalciMedica’s investors include SR One, Biogen Idec’s $200m New Ventures unit and venture capital firm Sanderling Ventures.
CalciMedica drew down the second…
